Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Rapid Micro Biosystems (Nasdaq: RPID) will release fourth quarter and full year 2025 financial results before market open on March 12, 2026.
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will release fourth quarter and full year 2025 financial results before market open on March 12, 2026.
Management will host a live webcast conference call at 8:30 a.m. ET on March 12, 2026, accessible via the company website; the webcast will be archived for replay after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RPID
In the Feb 25 session, RPID gained 6.30%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- March 12, 2026
- Scheduled release of Q4 and full year 2025 results
- Earnings time
- 8:30 a.m. ET
- Start time of webcast conference call
- Quarter reported
- Fourth quarter 2025
- Period to be reported with full year 2025
- Full year reported
- Full year 2025
- Annual financial results to be released
Historical Context
-
Inducement RSUs and stock options granted to new employees.
-
Record preliminary Q4 and full‑year 2025 revenue update.
-
Planned presentation at J.P. Morgan Healthcare Conference.
-
Announced $45 million growth capital commitment from Trinity Capital.
-
Q3 2025 results with raised full‑year revenue and placement guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2025 financial results prior to the market open on Thursday, March 12, 2026.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Thursday, March 12, 2026. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.